{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:27Z","timestamp":1740140667515,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA225655"],"award-info":[{"award-number":["R37CA225655"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Comprehensive genetic profiling using next-generation sequencing technologies has become an integral part of precision oncology. Variant annotation requires translating the DNA findings into protein level predictions. In this article we highlight inconsistencies in variant annotation for the MET D1228N exon 19 resistance mutations. MET D1228N and D1246N represent the same resistance mutation in MET exon 14 skipping alterations annotated on different transcripts. Additional examples of relevant variants annotated on different transcripts emphasize the importance of avoiding erroneous interpretation when realizing precision oncology.<\/jats:p>","DOI":"10.1002\/onco.13924","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T16:05:15Z","timestamp":1628093115000},"page":"e2297-e2301","source":"Crossref","is-referenced-by-count":5,"title":["<i>MET<\/i> D1228N and D1246N are the Same Resistance Mutation in <i>MET<\/i> Exon 14 Skipping"],"prefix":"10.1093","volume":"26","author":[{"given":"Jonathan M.","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital\/Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron N.","family":"Hata","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital\/Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-4978","authenticated-orcid":false,"given":"Jochen K.","family":"Lennerz","sequence":"additional","affiliation":[{"name":"Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital\/Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"2022011918113502300_onco13924-bib-0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"2022011918113502300_onco13924-bib-0002","article-title":"Comparison of annotation services for next-generation sequencing in a large-scale precision oncology program","volume":"4","author":"Katsoulakis","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2022011918113502300_onco13924-bib-0003","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/15384047.2019.1566049","article-title":"Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping","volume":"20","author":"Ding","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"2022011918113502300_onco13924-bib-0004","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lungcan.2016.11.006","article-title":"Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations","volume":"102","author":"Dong","year":"2016","journal-title":"Lung Cancer"},{"key":"2022011918113502300_onco13924-bib-0005","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","article-title":"Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models","volume":"23","author":"Engstrom","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022011918113502300_onco13924-bib-0006","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","article-title":"Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping","volume":"11","author":"Heist","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2022011918113502300_onco13924-bib-0007","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1158\/1078-0432.CCR-16-3273","article-title":"Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022011918113502300_onco13924-bib-0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/prot.1069","article-title":"Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: Modeling studies","volume":"44","author":"Miller","year":"2001","journal-title":"Proteins"},{"key":"2022011918113502300_onco13924-bib-0009","doi-asserted-by":"crossref","first-page":"8334","DOI":"10.1038\/sj.onc.1206052","article-title":"Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity","volume":"21","author":"Miranda","year":"2002","journal-title":"Oncogene"},{"key":"2022011918113502300_onco13924-bib-0010","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/j.clbc.2020.02.003","article-title":"Acquisition of cabozantinib-sensitive MET D1228N mutation during progression on crizotinib in MET-amplified triple-negative breast cancer","volume":"20","author":"Parsons","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"2022011918113502300_onco13924-bib-0011","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2019.11.010","article-title":"Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer","volume":"140","author":"Pruis","year":"2020","journal-title":"Lung Cancer"},{"key":"2022011918113502300_onco13924-bib-0012","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-10-4433","article-title":"A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients","volume":"71","author":"Tiedt","year":"2011","journal-title":"Cancer Res"},{"key":"2022011918113502300_onco13924-bib-0013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/onco.13545","article-title":"Acquired MET D1228N mutations mediate crizotinib resistance in lung adenocarcinoma with ROS1 fusion: A case report","volume":"26","author":"Wang","year":"2021","journal-title":"The Oncologist"},{"key":"2022011918113502300_onco13924-bib-0014","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2015-0510","article-title":"MET exon 14 skipping in non-small cell lung cancer","volume":"21","author":"Heist","year":"2016","journal-title":"The Oncologist"},{"key":"2022011918113502300_onco13924-bib-0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00401-018-1867-2","article-title":"K27\/G34 versus K28\/G35 in histone H3-mutant gliomas: A note of caution","volume":"136","author":"Leske","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2022011918113502300_onco13924-bib-0016","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/2261056b0","article-title":"Amino-acid sequence of slightly lysine-rich histone","volume":"226","author":"Iwai","year":"1970","journal-title":"Nature"},{"year":"2021","author":"Matched Annotation from NCBI and EMBL-EBI (MANE)","key":"2022011918113502300_onco13924-bib-0017"},{"key":"2022011918113502300_onco13924-bib-0018","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"key":"2022011918113502300_onco13924-bib-0019","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13924","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/12\/e2297\/42242697\/oncolo_26_12_e2297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/12\/e2297\/42242697\/oncolo_26_12_e2297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:18:27Z","timestamp":1642616307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/12\/e2297\/6511643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,8,17]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13924","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,8,17]]}}}